About Nectar Lifesciences Limited

Nectar Lifesciences Limited is a global pharmaceutical company specialising in cephalosporins, with a leadership position in 3rd and 4th generation cephalosporins supported by global approvals in 2024-25. The Company manufactures active pharmaceutical ingredients (APIs) and formulations, with capabilities in sterile injectables. It also operates an Empty Hard Gelatine Capsules (EHGC) facility serving both domestic and export markets, and has been engaged in the menthol business.

Operations are anchored by multiple manufacturing units across India, including facilities at Derabassi in Punjab, Bhatoli Kalan (Solan) in Himachal Pradesh, and Bari Brahmana in Jammu, alongside a dedicated formulation unit and an EHGC unit. The Company’s equity shares are listed on BSE Limited and the National Stock Exchange of India Limited, and its financial statements for the latest year were authorised for issue on July 07, 2025.

As on March 31, 2025, Nectar employed 1,786 people. The Company has 1 subsidiary (wholly owned), with negligible activity during the year; the contribution of the subsidiary to overall performance was stated as negligible.

Key milestones and developments in the latest year included the cancellation of all outstanding Global Depository Receipts (GDRs) and their delisting from the Luxembourg Stock Exchange with effect from November 28, 2024, and continued progress in cephalosporin R&D and operations. The Company also reported that its Baddi formulation facility operated at 78% utilisation, and the sterile injectable capacity remained fully operational during 2024-25.

Key Milestones of Nectar Lifesciences Limited

• Cancellation of all outstanding GDRs and delisting from the Luxembourg Stock Exchange in November 2024.
• Continued progress in cephalosporin research and development.
• Baddi formulation facility operated at 78% utilisation.
• Sterile injectable capacity remained fully operational during 2024-25.

Nectar Lifesciences Limited Business Verticals and Geographic Presence

The company’s business verticals include API and formulation manufacturing, sterile injectables, and Empty Hard Gelatine Capsules (EHGC). It serves both domestic and export markets with manufacturing facilities located across key Indian sites.

Manufactures and markets pharmaceutical active ingredients and formulations, with a specialty in cephalosporins and sterile injectables. It also operates an EHGC manufacturing facility and has been engaged in the menthol business.

Nectar Lifesciences Limited Key Management

• Mr. Sanjiv Goyal – Chairman & Managing Director
• Mr. Amit Chadah – Chief Executive Officer
• Mr. Sushil Kapoor – Chief Financial Officer
• Mr. Sanjaymohan Singh Rawat – Company Secretary
• Dr. Surulichamy Senethilkumar – Director (R & D)

Latest Updates on Nectar Lifesciences Limited

• Approved slump sale of API and formulations business to Ceph Lifesciences Private Limited for Rs 1,270 crore.
• Sale of menthol business assets to the same purchaser for Rs 20 crore.
• Post-transactions, company expects to become completely debt-free with proceeds utilised for growth and shareholder rewards.
• Efforts underway to dispose of EHGC manufacturing facility.
• Introduced four new cephalosporin APIs and filed three Drug Master Files (DMFs) in regulated markets in 2024-25.
• Baddi formulation facility at 78% utilisation across product categories.
• Complete cancellation and conversion of GDRs to equity shares.
• Employee transition planned post slump sale with headcount at 1,786 as on March 31, 2025.